araag2/HINT huggingface dataset:
Clinical trial NCT00275821 (phase 3, status: completed)
Conditions: age related macular degeneration
ICD codes: H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190
Drugs: ranibizumab 0.3 mg - 3 times monthly, then quarterly, ranibizumab 0.5 mg - 3 times monthly, then quarterly, ranibizumab 0.3 mg monthly
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with primary or recurrent subfoveal CNV secondary to AMD, including those
             with predominantly classic, minimally classic or occult lesions with no classic
             component

          -  Patients who have a BCVA score between 73 and 24 letters, inclusively, in the study
             eye using ETDRS-like grading charts (approximately 20/40 to 20/320)

        Exclusion Criteria:

          -  Prior treatment in the study eye with verteporfin, external-beam radiation therapy,
             subfoveal focal laser photocoagulation, vitrectomy, or transpupillary thermotherapy.

          -  History of submacular surgery or other surgical intervention for AMD in the study eye,
             glaucoma filtration surgery, corneal transplant surgery.

          -  Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within one month
             preceding Baseline.

        Other protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT00646620 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol (symbicort), fluticasone/salmeterol (advair diskus), albuterol (ventolin)
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CC(C)(C)NCC(O)C1=CC(CO)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of asthma and baseline lung function test results as determined by protocol

          -  Required and received asthma maintenance therapy within previous 4 weeks at doses
             determined by protocol

        Exclusion Criteria:

          -  Severe asthma or asthma markedly affected by seasonal factors

          -  Has required treatment with any non-inhaled corticosteroids within previous 4 weeks,
             has sensitivity to drugs specified in the protocol or requires treatment with
             beta-blockers
Clinical trial NCT00482612 (phase 3, status: completed)
Conditions: insomnia
ICD codes: F51.01, F51.02, F51.03, F51.04, G47.00, G47.09, A81.83
Drugs: esmirtazapine, placebo
SMILES: [H][C@]12CN(C)CCN1C1=C(CC3=CC=CC=C23)C=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Has signed written informed consent after the scope and nature of the investigation
             was explained to them

          -  Has difficulty falling asleep, maintaining sleep or has early morning awakenings

        Exclusion Criteria:

          -  Significant medical or psychiatric illness causing sleep disturbances

          -  Has a history of bipolar disorder or family (immediate family) of suicide

          -  Has sleep disorder such as sleep related breathing disorder, restless leg syndrome,
             narcolepsy

          -  Has significant other medical illness such as acute or chronic pain, heart, kidney or
             liver disease within the last year

          -  Currently diagnosed or meets the criteria for Major Depressive Disorder (MDD) or has
             been treated for MDD with the last 2 years

          -  Substance abuse, excessive use of alcohol (as determined by the physician) or drug
             addiction within the last year.
Clinical trial NCT00150176 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: asenapine - open label, placebo - double blind, asenapine - double blind
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Have a primary diagnosis of schizophrenia

          -  History of at least 1 prior episode of acute schizophrenia in the 3 years preceding
             screening

          -  History of schizophrenia requiring continuous antipsychotic treatment for at least 1
             years preceding screening

          -  Clinically stable at the time of entry defined by at least a 4 week period of stable
             symptoms

        Key Exclusion Criteria:

          -  Have an uncontrolled, unstable clinically significant medical condition

          -  History of suicide attempt or significant violence to others in the past 2 years

          -  A substance-induced psychotic disorder or behavioral disturbance thought to be due to
             substance abuse

          -  Current substance abuse/dependence

          -  Concurrent psychiatric disorder other than schizophrenia.
Clinical trial NCT00484198 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: pioglitazone, placebo, rivoglitazone hcl, rivoglitazone hcl
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C2N=C(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)N(C)C2=C1, COC1=CC=C2N=C(COC3=CC=C(CC4SC(=O)NC4=O)C=C3)N(C)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes

          -  Male or female at least 18 years of age

          -  A1C > 7% and less or equal to 8.5%

          -  Non-fasting C-peptide > 0.5ng/mL

          -  Current monotherapy treatment with stable dose of approved non-TZD antihyperglycemic
             medication for greater or equal to 3 months prior to screening or

          -  Untreated with any antihyperglycemic agent during 2 months prior to screening

        Exclusion Criteria:

          -  History of type 1 diabetes or ketoacidosis

          -  History of long-term therapy with insulin

          -  BMI > 45 kg/m2

          -  Known history of CHF

          -  Impaired hepatic function

          -  History of prior treatment failure with, or intolerance of, a TZD

          -  Contraindication to treatment with pioglitazone

          -  Treatment with fibrates

          -  If untreated with oral antihyperglycemic, considered to have failed diet and exercise
             modification as sole treatment for type 2 diabetes
Clinical trial NCT01271933 (phase 3, status: completed)
Conditions: fibromyalgia
ICD codes: M79.7
Drugs: pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have fibromyalgia.

        Exclusion Criteria:

          -  Patients with other painful conditions cannot participate.
Clinical trial NCT00220233 (phase 3, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: olmesartan medoxomil, amlodipine, hydrochlorothiazide
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Without antihypertensive pre-treatment mean seated BP greater than 160/100 mmHg

          -  Pre-treatment with amlodipine 5 or 10 mg: mean seated BP greater than or equal to
             140/90 mmHg

        Exclusion Criteria:

          -  Secondary hypertension

          -  Any serious disorder which may limit the ability to evaluate the efficacy or safety of
             the test drugs
Clinical trial NCT00272285 (phase 3, status: completed)
Conditions: vomiting, nausea
ICD codes: R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8, R11.0, R11.11, R11.2
Drugs: ramosetron, granisetron
SMILES: CN1C=C(C(=O)[C@@H]2CCC3=C(C2)N=CN3)C2=C1C=CC=C2, CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[C@H](C2)N3C)C2=C1C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Subject with age between 20-74 years old (inclusive) of either sex

          -  Cancer subject is scheduled to receive the designated chemotherapy programs

          -  Subject without symptoms of vomiting for at least one week before dosing trial
             medication

          -  Subject with ECOG performance status scale no greater than 2

          -  Subject has signed the written informed consent form

        Exclusion Criteria:

          -  Subject has received radiotherapy to the abdomen or pelvis within 4 weeks before
             entering this study

          -  Subject has received the designated chemotherapy programs within 6 months before
             entering the study

          -  Subject has known heart failure or myocardial infraction or with laboratory
             abnormalities at screening

          -  Subject has known concurrent diseases that may cause vomiting

          -  Subject has taken medications that could influence the outcome of the study within 3
             days before entering the study

          -  Subject with a history of allergy or intolerance to ramosetron, granisetron or
             dexamethasone

          -  Female subject who is pregnant or breastfeeding

          -  Subject with life expectancy less than 3 months

          -  Subject participated other investigational drug trial within 1 month before entering
             this study
Clinical trial NCT00639158 (phase 3, status: completed)
Conditions: dyslipidemias, coronary heart disease, combined (atherogenic) dyslipidemia, mixed dyslipidemia
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118, D81.89, D81.9, F90.2, Z73.812, D81.0, H25.813, D81.31
Drugs: abt-335, placebo, atorvastatin, ezetimibe
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with mixed dyslipidemia (trigylcerides, > or = to 150 mg/dL to < 400 mg/dL;
             HDL-C < 40 mg/dL for males, < 50 mg/dL for females; LDL-C, > or = to 130 mg/dL).

          -  Subjects must agree to use adequate birth control methods and to adhere to the
             American Heart Association (AHA) Diet.

        Exclusion Criteria:

          -  Subjects with unstable or uncontrolled medical conditions considered inappropriate in
             a clinical trial.

          -  Subjects with an unstable dose of medications or receiving Coumadin, oral, intravenous
             or intramuscular cyclosporine, statins, or certain other medications.

          -  Women who are pregnant or plan on becoming pregnant, or women who are lactating.
Clinical trial NCT00480610 (phase 3, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: tacrolimus ointment, placebo ointment
SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patient of any ethnic group

          -  Patient was at least 16 years old and suffered from mild to severe atopic dermatitis
             (Rajka/Langeland score of at least 3)

        Exclusion Criteria:

          -  Patient had a genetic epidermal barrier defect such as Netherton's syndrome or
             generalised erythroderma

          -  Patient had a clinically significant skin infection on the affected (and to be
             treated) area
Clinical trial NCT00518895 (phase 3, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: dacarbazine plus genasense, dacarbazine plus placebo
SMILES: N1C=CN=C1, [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of melanoma

          -  Progressive disease that is not surgically resectable, or metastatic Stage IV

          -  Low-normal LDH, defined as ≤ 0.8 times the upper limit of normal

          -  No prior chemotherapy

          -  Measurable disease

          -  ECOG performance status ≤ 1

          -  At least 4 weeks and recovery from effects of major prior surgery or other therapy,
             including immunotherapy, radiation therapy, or cytokine, biologic or vaccine therapy

          -  Prior immunotherapy allowed

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior cytotoxic chemotherapy, including regional perfusion, or prior Genasense
             treatment

          -  Primary ocular or mucosal melanoma

          -  Bone-only metastatic disease

          -  History or presence of brain metastasis or leptomeningeal disease

          -  Significant medical disease other than cancer

          -  Organ allograft
Clinical trial NCT00596817 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: placebo, vortioxetine (lu aa21004)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Major Depressive Episode (MDE) as the primary diagnosis according to DSM-IV TR
             criteria

          -  At least one other MDE before the current one

          -  Moderate to severe depression

        Exclusion Criteria:

          -  Any current psychiatric disorder other than Major Depressive Disorder (MDD) as defined
             in the DSM-IV TR

          -  Any substance disorder within the previous 6 months

          -  Female patients of childbearing potential who are not using effective contraception

          -  Use of any psychoactive medication 2 weeks prior to screening and during the study

        Randomisation Criteria: Patients in remission (MADRS total score <=10) at both Week 10 and
        Week 12

        Other protocol-defined inclusion and exclusion criteria may apply.
Clinical trial NCT00464373 (phase 3, status: terminated)
Conditions: chronic prostatitis with chronic pelvic pain syndrome, prostatitis
ICD codes: A54.22, A59.02, N41.0, N41.1, N41.4, A54.22, A59.02, N41.0, N41.1, N41.4
Drugs: botulinum toxin type a, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  CPPS NIH III (symptoms over 3 months during the last 6 months, 4 glass-test)

          -  Pain Score ≥ 4

        Exclusion Criteria:

          -  During the last month: intake of antibiotics, alpha receptor blockers,
             anticholinergics; intake of analgesics containing opioids (longer than 4 days);
             participating in a different clinical trial

          -  During the last 3 months:documented urinary infection, epididymitis, positive urinary
             culture; status post biopsy of the prostate gland; STD: Gonorrhea, Chlamydia,
             Mycoplasm, Trichomonads

          -  During the last 6 months: Finasteride or any other 5α-reductase inhibitor

          -  During the last 12 months: status post any surgery on the prostate gland; genital
             herpes; not adjustable hypertension, angina pectoris, heart failure (NYHA III-IV),
             Status post myocardial infarction, coronary bypass surgery or coronary dilatation

          -  During the last 24 months: cerebral insult, TIA; active disease of the liver

          -  Other urological diseases like prostate cancer, bladder cancer, status post radiation
             of the small pelvis, chemotherapy (intravesical or systemic)

          -  Urinary catheter

          -  Residual urine > 200ml

          -  Serum creatinine > 200µmol/l

          -  Status post injection of BTX A, hypersensitivity concerning any substances of content
             of BTX, myasthenia gravis

          -  Any kind of cancer

          -  Active inflammation (except the prostate gland)

          -  Neurological or psychological disease making signing of a consent form or behaving
             according to a study protocol impossible

          -  Abuse of drugs or alcohol during last 5 years

          -  Any disease that may influence the results according to the opinion of the medical
             doctor
Clinical trial NCT01363440 (phase 3, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: intravitreal aflibercept injection (iai; eylea®; bay86-5321)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

        The following is an abbreviated list of inclusion criteria:

          -  Adults ≥ 18 years with type 1 or 2 diabetes mellitus

          -  Decrease in vision determined to be primarily the result of DME in the study eye

          -  BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye

        Exclusion Criteria:

        The following is an abbreviated list of exclusion criteria:

          -  Laser photocoagulation (panretinal or macular) in the study eye within 90 days of day
             1

          -  Previous use of intraocular or periocular corticosteroids in the study eye within 120
             days of day 1

          -  Previous treatment with anti-angiogenic drugs in the study eye (pegaptanib sodium,
             bevacizumab, ranibizumab, etc.) within 90 days of day 1

          -  Active proliferative diabetic retinopathy (PDR) in the study eye

          -  Uncontrolled diabetes mellitus

          -  Only 1 functional eye even if that eye is otherwise eligible for the study
Clinical trial NCT00721760 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: enoxaparin sodium, semuloparin sodium, placebo
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], \N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Standard surgery for fracture of the upper third of the femur including femoral head
             and neck.

        Exclusion Criteria:

          -  Estimated time of injury/fracture > 24 hours before admission to hospital;

          -  Any major orthopedic surgery in the 3 months prior to study start;

          -  Multiple trauma affecting more than one organ system;

          -  Deep vein thrombosis or pulmonary embolism within the last 12 months or known
             post-phlebitic syndrome;

          -  High risk of bleeding;

          -  Known allergy to heparin, or enoxaparin, or pork products;

          -  End stage renal disease or patient on dialysis;

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01541371 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone er
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Participants meeting Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV)
             diagnosis criteria of schizophrenia

          -  Participant receiving full course of treatment (6-8 weeks) at correct dose (dose range
             recommended by the instruction) of Risperdal, Zyprexa or Seroquel before enrollment,
             was poorly controlled and had to change medication because of unsatisfying efficacy,
             tolerability or safety issues, or other reason

          -  Participant in the non-acute phase during screening received treatment with any of
             above three antipsychotics within 4 weeks before enrollment and state of illness was
             relatively stable

          -  7. Female participants must be postmenopausal for at least 1 year, surgically sterile,
             abstinent, or, if sexually active, agree to practice an effective method of birth
             control before entry and throughout the study. Effective methods of birth control
             include prescription hormonal contraceptives, contraceptive injections, intrauterine
             devices, double barrier method, contraceptive patch and male partner sterilization.
             Female participants must also have a negative urine pregnancy test at screening

          -  Participant willing to and who could complete questionnaire by himself

        Exclusion Criteria:

          -  Participant receiving treatment with clozapine or risperidone microspheres for
             injection (Hengde) within 3 months before screening

          -  Participant having history of seizure except febrile convulsion (seizures that occur
             during a febrile episode [fever])

          -  Participant having refractory schizophrenia (previous treatment with unsatisfied
             efficacy of 2 or more than 2 kinds of antipsychotics with different chemical structure
             after adequate dose and duration)

          -  Participant receiving electric shock treatment within 1 month before screening

          -  Participant having serious, unstable physical diseases
Clinical trial NCT00042887 (phase 3, status: terminated)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: mitomycin c
SMILES: CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Cytologically confirmed solitary primary or recurrent papillary transitional cell
             carcinoma of the bladder

               -  Ta or T1

          -  Tumor no greater than 2 cm in diameter

          -  Negative urine cytology

          -  No suspicious lesions in bladder requiring biopsy

          -  No tumors in the prostatic urethra or upper urinary tract

          -  No prior history of T1 G3 tumors, muscle invasive tumors (T2 or greater), or carcinoma
             in situ

        PATIENT CHARACTERISTICS:

        Age

          -  80 and under

        Performance status

          -  WHO 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  HIV negative

          -  No active intractable or uncontrollable bladder infection

          -  No urethral strictures that would preclude endoscopic procedures or repeated
             catheterization

          -  No prior or concurrent congenital or acquired immune deficiency syndrome

          -  No other prior or concurrent malignancy except cured basal cell skin cancer or
             intraepithelial cancer of the cervix

          -  No prior or concurrent leukemia or Hodgkin's disease

          -  No concurrent disease for which general anesthesia is contraindicated

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance

          -  Not pregnant or nursing

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 12 months since prior BCG vaccine

        Chemotherapy

          -  At least 1 year since prior mitomycin

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior pelvic radiotherapy

        Surgery

          -  No prior organ transplant

        Other

          -  At least 3 months since prior intravesical treatment